Harvard Bioscience(US:HBIO) Globenewswireยท2025-07-17 11:00Leadership Transition - Harvard Bioscience announced a CEO succession plan with John Duke set to become President & CEO on July 28, 2025, following Jim Green's retirement after over 8 years as Chairman and 6 years as President & CEO [1][3] - John Duke has a strong background, previously serving as CEO of Plastic Molding Technology with approximately 20% annual revenue growth, and has over 20 years of experience at Corning Incorporated [2][3] Board Appointments - The company appointed Rob Gagnon and Seth Benson to the Board of Directors effective July 16, 2025 [3][6] - Rob Gagnon has over 20 years of experience in global finance operations in the life sciences industry and previously served as CFO of Harvard Bioscience from 2013-2018 [4] - Seth Benson has significant leadership experience in finance and technology, currently serving as CFO of Nuclera Ltd [5] Financial Performance - Harvard Bioscience expects second quarter 2025 revenue to be $20.4 million and has reiterated its gross margin guidance of 55% to 57% for the same period [7][8]